Clinuvel Pharmaceuticals Ltd CLVLF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $5.92
- Day Range
- $5.87–5.89
- 52-Week Range
- $5.87–8.60
- Bid/Ask
- $3.99 / $406.75
- Shares Outstanding
- 50.43M
- Market Cap
- $297.02M
- Volume/Avg
- 350 / 3,320
Key Statistics
- Price/Earnings (Normalized)
- 12.82
- Price/Sales
- 4.70
- Dividend Yield (Trailing)
- 0.61%
- Dividend Yield (Forward)
- 0.61%
- Dividend Payment Schedule
- Sep
- Total Yield
- 0.61%
Company Profile
Clinuvel Pharmaceuticals Ltd is a biopharmaceutical firm focused on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders. Its portfolio is centred around melanocortin peptides, with programs advancing in photomedicine and vitiligo. The company's main therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the U.S.A., Canada, Israel, and Australia as a systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). Additionally, the firm is focused on developing and manufacturing Neuracthel to target neurological, endocrinological, and degenerative disorders. Geographically, it derives key revenue from Ireland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 16
- Website
- https://www.clinuvel.com
Valuation
|
Metric
|
CLVLF
|
|---|---|
Price/Earnings (Normalized) | 12.82 |
Price/Book Value | 1.58 |
Price/Sales | 4.70 |
Price/Cash Flow | 11.96 |
Price/Earnings
CLVLF
Financial Strength
|
Metric
|
CLVLF
|
|---|---|
Quick Ratio | 2.33 |
Current Ratio | 14.81 |
Interest Coverage | — |
Quick Ratio
CLVLF
Profitability
|
Metric
|
CLVLF
|
|---|---|
Return on Assets (Normalized) | 12.18% |
Return on Equity (Normalized) | 13.36% |
Return on Invested Capital (Normalized) | 10.40% |
Return on Assets
CLVLF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@R<<Jv | LOCK|#?<zz | $138B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|dwl<KF | LOCK|?QB$ | $85B | |||
| argenx SE ADR
ARGX
| LOCK|TTpjtf | LOCK|%q | $65B | |||
| Moderna Inc
MRNA
| LOCK|&@c^M% | LOCK|Y# | $58B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<%^?lb | LOCK|dW | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|n$%^<^ | LOCK|lBDZ< | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&z<q?wXP | LOCK|$?T@@ | $28B | |||
| BioNTech SE ADR
BNTX
| LOCK|hqdb!k | LOCK|j>M | $26B | |||
| Incyte Corp
INCY
| LOCK|%^>#Vq | LOCK|F&< | $26B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|q^%qqc! | LOCK|^VH | $16B |
United States